leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix Group - Commencement of facility expansion plan

RNS Number : 9489T
Tissue Regenix Group PLC
24 July 2020
 

Tissue Regenix Group plc

 

Commencement of facility expansion plan

 

Leeds, 24 July 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group"), the regenerative medical devices company, announces that following the recent completion of its successful fundraising, the Company has commenced the first phase of its planned manufacturing capacity expansion programme in San Antonio, TX, which represents a key element of the Group's commercial development plan.

 

The expansion programme will be split into several phases. The first phase is expected to take approximately six months to complete and will include the development of operational capabilities in the new 21,000sq.ft building to house freezers and distribution functions that will free up space for additional sterile packaging clean rooms to be built in the existing facility. The Board is also evaluating the possibility of combining some elements of the later phases into this initial work in order to minimise future potential disruption and the overall costs associated with the expansion programme.

 

Demand for the Group's products, in particular the BioRinse orthopaedic product portfolio, continues to grow and the first phase will allow for an uplift of approximately 50 percent to the Group's current BioRinse processing capacity. 

 

Gareth Jones, Interim Chief Executive Officer of Tissue Regenix Group, commented: 

"I am delighted to confirm the commencement of the first phase of our investment and expansion plan. Not only do we expect this investment to provide the additional capacity required to efficiently scale our business and drive further commercial growth, it will also increase the number of patients who can benefit from our broadening product portfolio."

 

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson, Head of Communications  

 

Tel: 0330 430 3073



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Alex Price / Ben Maddison

Tel: 0207 710 7600

 



FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAPXDASEEEFA

Quick facts: Tissue Regenix Group PLC

Price: 0.35

Market: AIM
Market Cap: £24.62 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20